Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

IntelGenx and Endo Ink Pact for New Oral Film Product in U.S.

By IntelGenx Technologies Corp. | December 28, 2016

IntelGenx announces development and commercialization agreement with Endo Ventures.

IntelGenx Corp. announced that it has entered into a co-development and commercialization agreement with Endo Ventures Ltd. for a new product utilizing IntelGenx’ proprietary VersaFilm™ for the U.S. market.

Under the agreement, Endo has obtained certain exclusive rights to market and sell IntelGenx’ product in the U.S. IntelGenx will receive an upfront payment and future milestone payments. Endo and IntelGenx will share the profits of commercialization.

“We are thrilled to further strengthen our partnership with such a significant global pharmaceutical organization as Endo,” said Dr. Horst Zerbe, president and CEO of IntelGenx. “We see the completion of this deal as further validation of our VersaFilm™ technology and our ability to enter into high quality partnerships. IntelGenx continues to make tremendous progress in executing our strategy of becoming a global leader in pharmaceutical oral films.”

IntelGenx is an oral drug delivery company primarily focused on the development and manufacturing of pharmaceutical oral films based on its proprietary VersaFilm™ technology platform. The Montreal-based company was established in 2003.

IntelGenx provides services to pharmaceutical partners. Its offerings include R&D, analytical method development, clinical monitoring, IP and regulatory services. The IntelGenx manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities. www.intelgenx.com.

(Credit: Marketwired)


Filed Under: Drug Discovery

 

Related Articles Read More >

Isomorphic Labs illustration of floating pink, peach and gold cubes against a peach-to-pink gradient
Isomorphic Labs adds Merck as an oncology partner after $5 billion raise
Recursion Pharmaceuticals Logo
Recursion’s Phase 3 FAP trial will count large-polyp removals as events under FDA-agreed design
Ball-and-stick model of the cancer drug imatinib
After six years in stealth, Humanitas bets on hybrid AI for drug discovery
NIH is reorganizing clinical trial funding by trial type instead of disease
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE